U.S. Sexual Health Testing Market Size By Disease Type(Chlamydia, Trichomonas, Gonorrhea, HPV, HSV), By Type of Testing(Molecular Test, Immunology Assay, Culture/Isolation Of Organisms), By Sample Type(Blood Based, Urine Based, Oral-Fluid Based), By Device(Laboratory Devices and Point of Care (POC) Devices), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online), By Geographic Sco

U.S. Sexual Health Testing Market Size And Forecast

U.S. Sexual Health Testing Market size was valued at USD 23.3 Billion in 2024 and is projected to reach USD 43.69 Billion by 2031, growing at a CAGR of 7.49% from 2024 to 2031.

Sexually transmitted diseases are common and millions of new infections occur each year in the United States. Rising number of sexually transmitted diseases propelling the demand for sexual health testing near future. The U.S. Sexual Health Testing Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

U.S. Sexual Health Testing Market Definition

Sexual health testing is the combination of different tests and several different methods that are used for the diagnosis and detection of sexually transmitted diseases such as Chlamydia, Gonorrhea, Trichomonas, HIV, HSV, HCV, HPV, and rest of others. Four major types of testing including Culture/Isolation Of Organisms, Molecular Test, Immunology Assay, and others, are used for sexual health testing. HIV can be diagnosed through three types of HIV tests such as antibody tests, antigen/antibody tests, and nucleic acid tests (NAT).

The prevalence of STDs across the American population is growing with growing new cases each year. In addition to other sexually transmitted diseases (STDS), the rate of HIV per 100,000 people in the Mid-West region of the US. As shown in the above diagram, the population across Illinois is having highest new HIV diagnosis rate per 100,000 people across the state. In 2020, Illinois accounted for the new HIV diagnosis rate of 11.7 per 100,000 people.

The prevalence of sexually transmitted diseases (STDS) is growing. As shown in the above figure, the rate of Chlamydia per 100,000 population across Kansas state is higher. In 2019, the Chlamydia rate per 100,000 Kansas population was 524.8; however, in 2020 the rate decreased as it was 505.3 per 100,000 Kansas population. On the other hand, the rate of Gonorrhea increased by 13.94% in 2020 as compared to 2019. In 2019, the rate of Gonorrhea per 100,000 Kansas population was 169.3 while the same in 2020 was 192.9 per 100,000 Kansas population. Such factors are driving the growth of the US Sexual Health Testing Market.

U.S. Sexual Health Testing Market Overview

Sexually transmitted disease (STD), is also known as sexually transmitted infection. It can be defined as, a pathogen that causes infection through sexual contact, this recognizable condition is termed a sexually transmitted disease. Sexually transmitted diseases are common and millions of new infections occur each year in the United States. Rising number of sexually transmitted diseases propelling the demand for sexual health testing near future.

Chlamydia, Gonorrhea, Trichomonas, Syphilis, HIV, Herpes Simplex Virus (HPV), Pelvic Inflammatory disease (PID), and, HSV are some common Sexually Transmitted Diseases found in the United States heavily. For instance, according to the Center for Disease Control and Prevention (CDC), the number of STD patients in the United States are rising continuously for the past few years with no sign of slowing. Since about ten years ago, more people have been getting syphilis and gonorrhea than before. According to the CDC’s most current prevalence estimate, one in five Americans has one of the prevalent STDs on any specific day. About 2.5 million cases of Chlamydia, Gonorrhea, and syphilis were found in the U.S. in 2021. And, near about 68 million sexually transmitted infections patients were found in 2018. Additionally, about 1.2 million people are living with HIV in the United States.

Furthermore, the rising cases of gonorrhea and syphilis and government support for sexual health awareness are creating new opportunities for the market to grow over forecasted period. according to early data from the U.S. Centers for Disease Control and Prevention, the number of new cases of syphilis, gonorrhea, and chlamydia all increased in 2021. According to CDC statistics, Syphilis occurrences increased by 26% between 2020 and 2021, which shows that at least 52,354 primary and secondary syphilis cases were reported in 2017. While the overall number of cases reached its greatest level since 1948, this was the highest rate of infections since 1991. Moreover, according to CDC data, American Indians and Alaska Native people have the highest rate of syphilis infections. While these illnesses afflict men more frequently than women when they have sex with other guys. Between 2020 and 2021, the rates of the three most common STDs, including chlamydia and gonorrhea, increased overall by 4.4%.

However, lack of awareness, discrimination about sexual health, concern regarding data privacy, and data breaching and confidentiality issue may hamper the sexual health testing market near future. Some groups of people may find it difficult to access sexually transmitted disease testing services due to confidentiality concerns, such as concerns that their parents would learn. And, some sexual or reproductive health-related services have been avoided by youngsters due to concerns about confidentiality. For instance, 12.7% of sexually active young people in the U.S. who were covered by their parent’s health insurance did not seek sexual and reproductive health care because they were worried that their parents could find out. This was highest among those between the ages of 15 and 17 (22.6%).

U.S. Sexual Health Testing Market Segmentation Analysis

The U.S. Sexual Health Testing Market is segmented based on Disease Type, Type of Testing, Sample Type, Device, And Distribution Channel.

U.S. Sexual Health Testing Market, By Disease Type

• Chlamydia• Trichomonas• Gonorrhea• HPV• HSV• HIV• HCV• Others

To Get Summarized Market Report By Disease Type-

Based on Disease Type, the market is segmented into Chlamydia, Trichomonas, Gonorrhea, HPV, HSV, HIV, HCV, and Others. The Chlamydia segment is holding the largest market share and projected to grow with a CAGR of 7.89% during the forecast period. Untreated chlamydia infections can lead to serious health issues including pelvic inflammatory disease (PID) and infertility. According to CDC, about 1.5 million cases of Chlamydia were reported in 2020. Detecting chlamydia can be done through the home-to-lab channel. The majority of home-to-lab chlamydia tests are self-collection kits, which let consumers collect a urine sample or swab at home and send it to a lab. A physician might advise laboratory-based confirmation testing if home to lab chlamydia test is positive. Everly Well, Inc, LetsGetChecked, Lemonaid Health, Nurx, MyLab Box, STD Check companies provide home to lab chlamydia test in the U.S.

U.S. Sexual Health Testing Market, By Type of Testing

• Molecular Test• Immunology Assay• Culture/Isolation Of Organisms• Others

By Type of Testing, US Sexual Health Testing Market is classified as Molecular Test, Immunology Assay, Culture/Isolation Of Organisms, and Others. Molecular Test segment accounted for the largest market share in 2021 and expected to grow with a significant CAGR of 7.25% during the forecasted period. Molecular human papillomavirus (HPV) assays examine viral DNA fragments to determine their HPV content. There are numerous tests that can be used by scientists to look for HPV. For example, “Aptima® HBV Quant Assay” from Hologic Inc. is a molecular HBV treatment management assay with dual-target design. In high-income nations, accurate Sexually Transmitted Infection (STI) diagnostic tests (using molecular technology) are frequently employed. These are especially helpful for asymptomatic infection diagnosis. For chlamydia and gonorrhoea, they are, however, mostly unavailable in low- and middle-income (LMIC) nations.

U.S. Sexual Health Testing Market, By Sample Type

• Blood Based• Urine Based• Oral-Fluid Based• Others

Based on Sample Type analysis, the US Sexual Health Testing Market is classified into Blood Based, Urine Based, Oral-Fluid Based, and Others. Blood Based holds a highest market share in 2021 and is projected to grow with highest CAGR of 8.12% during the forecast period. The most commonly used sample type for the detection of sexually transmitted diseases is blood. Cells, chemicals, proteins, and other blood components can also be measured or examined through blood tests. A routine exam frequently includes blood work.

Additionally, blood samples are used toassist in the diagnosis of several illnesses and conditions. Blood samples are also used to check on a patient’s medical therapy progress for chronic diseases like diabetes or high cholesterol. Blood tests can diagnose many sexually transmitted infections, including hepatitis B, genital herpes, HIV, and syphilis. A blood sample is taken via venipuncture, dry blood spot, or capillary draw and delivered to a lab for testing to identify HIV.

U.S. Sexual Health Testing Market, By Device

• Laboratory Devices• Point of Care (POC) Devices

By Device, US Sexual Health Testing Market is classified as Laboratory Devices and Point of Care (POC) Devices. Laboratory Devices segment accounted for the largest market share in 2021 and is projected to grow with highest CAGR of 7.23% during the forecast period. There have been continuous product launches in molecular diagnostics, one of the key drivers behind the expansion of laboratory testing and devices. More product introductions allow laboratories to install the instruments or equipment they need. For instance, in May 2022, Qiagen Inc. introduced NeuMoDxHSV 1/2 Quant Assay to quantify and differentiate herpes simplex virus type 1 (HSV-1) DNA and/or herpes simplex virus type 2 (HSV-2). The development of this assay enables the company to expand its offering in laboratory testing, which ultimately aids in market expansion owing to the cutting-edge tests.

U.S. Sexual Health Testing Market, By Distribution Channel

• Hospital Pharmacies• Retail Pharmacies• Online• Others

To Get Summarized Market Report By Distribution Channel-

By Distribution Channel, US Sexual Health Testing Market is classified as Hospital Pharmacies, Retail Pharmacies, Online, and Others. Hospital Pharmacies segment accounted for the largest market share in 2021 and is projected to grow with highest CAGR of 7.61% during the forecast period. Most diagnostic testing cases are also carried out in hospitals after consulting with doctor which is anticipated to increase demand for STD diagnostics testing market even further. Laboratory tests are widely used in hospitals and have a high level of accuracy, so people tend to place more trust in laboratory tests. Monitoring the use of medications in hospitals and other medical facilities is the main responsibility of hospital pharmacies. The selection, prescription, procurement, delivery, administration, and review of pharmaceuticals are among the objectives which aim to improve patient outcomes. Patient Preference and Clinical Testing for sexually transmitted disease testing is expected to fuel growth of segment. Medical experts typically test for the most prevalent diseases, such as gonorrhea, HIV, and chlamydia.

Key Players

The major players in the market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Danaher Corporation, Quest Diagnostics Incorporated., and Others.

This section provides a company overview, ranking analysis, company regional and industry footprint, and

Key Developments

• In December 2022, Thermo Fisher Scientific, launched the TrueMark Infectious Disease Research Panels designed to enable rapid and accurate detection and categorization for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases

• In May 2022, Alinity m STI Assay has been approved by the FDA, according to an announcement from Abbott. The test simultaneously identifies and differentiates four sexually transmitted infections (STIs). Untreated STIs can result in serious health issues, such as an increased chance of developing certain malignancies and infertility

• In December 2021, for use on the cobas 5800 System in countries that accept the CE Mark, Roche launched the first infectious disease assays as well as the cobas omni Utility Channel. These will be the first tests made available for use on the brand-new cobas 5800 System to assist patient management of the hepatitis B and c viruses, as well as the human immunodeficiency virus

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.

Market Attractiveness